Literature DB >> 9265661

Catheter-directed lysis of iliofemoral vein thrombosis with use of rt-PA.

R Verhaeghe1, L Stockx, H Lacroix, J Vermylen, A L Baert.   

Abstract

The aim of our study was to evaluate the results of catheter-directed thrombolysis and complementary procedures to treat acute iliofemoral deep vein thrombosis (DVT). A total of 24 consecutive patients with acute iliofemoral DVT underwent intrathrombus drip infusion of alteplase (3 mg/h; mean dosage 86 mg, range 45-174 mg), while intravenous heparin (1000 U/h) was continued. Complementary procedures were hydrodynamic thrombectomy in 3 and primary insertion of a Wallstent in 9 patients. Patency of 19 thrombosed veins (79 %) was restored with prompt symptomatic relief. An underlying anatomical anomaly or lesion was present in 13 patients: iliac vein compression syndrome (n = 8), absent (n = 2) or obstructed (n = 1) vena cava or venous stenosis (n = 2). Ten of the abnormalities were unknown before lysis and eight were relieved by stent deployment. Puncture site bleeding was the only complication but led to transfusion in 6 patients (25 %). Symptomatic reocclusion occurred in 4 patients. Catheter thrombolysis of iliofemoral vein thrombosis revealed many anatomical abnormalities which may predispose to thrombosis and are often amenable to stenting.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9265661     DOI: 10.1007/s003300050239

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  11 in total

1.  Deep Vein Thrombosis.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-06

2.  Usefulness of catheter-directed thrombolysis using alteplase in peripheral vascular occlusion.

Authors:  J Chan; C R Rees; A K Song; S Pham
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-01

3.  Catheter-directed thrombolytic therapy for thoracic deep vein thrombosis is safe and effective in selected patients with and without cancer.

Authors:  Geert Maleux; Pieter Marchal; Marleen Palmers; Sam Heye; Peter Verhamme; Johan Vaninbroukx; Raymond Verhaeghe
Journal:  Eur Radiol       Date:  2010-03-28       Impact factor: 5.315

4.  EkoSonic Thrombolysis as a Therapeutic Adjunct in Venous Occlusive Disease.

Authors:  D S Zaghlool; R W Franz; J Jenkins
Journal:  Int J Angiol       Date:  2016-04-03

5.  Real-time feedback of histotripsy thrombolysis using bubble-induced color Doppler.

Authors:  Xi Zhang; Ryan M Miller; Kuang-Wei Lin; Albert M Levin; Gabe E Owens; Hitinder S Gurm; Charles A Cain; Zhen Xu
Journal:  Ultrasound Med Biol       Date:  2015-01-23       Impact factor: 2.998

6.  Percutaneous mechanical and pharmacomechanical thrombolysis for occlusive deep vein thrombosis of the proximal limb in adolescent subjects: findings from an institution-based prospective inception cohort study of pediatric venous thromboembolism.

Authors:  Neil A Goldenberg; Brian Branchford; Michael Wang; Charles Ray; Janette D Durham; Marilyn J Manco-Johnson
Journal:  J Vasc Interv Radiol       Date:  2011-01-08       Impact factor: 3.464

7.  Catheter-directed thrombolysis with conventional aspiration thrombectomy for lower extremity deep vein thrombosis.

Authors:  Yong Sun Jeon; Yong Han Yoon; Joung Ym Cho; Wan Ki Baek; Kwang Ho Kim; Kee Chun Hong; Joung Taek Kim
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

Review 8.  Deep vein thrombosis: current status and nanotechnology advances.

Authors:  Aniket S Wadajkar; Sonia Santimano; Maham Rahimi; Baohong Yuan; Subhash Banerjee; Kytai T Nguyen
Journal:  Biotechnol Adv       Date:  2012-08-23       Impact factor: 14.227

Review 9.  [Fibrinolytic therapy of deep vein thrombosis].

Authors:  B Weidmann; W Jansen; B Franzen; M Tauchert
Journal:  Med Klin (Munich)       Date:  1999-03-15

10.  Transcatheter thrombolytic therapy for symptomatic thrombo-occlusion of inferior vena cava filter.

Authors:  Liang Xiao; Jing Shen; Jia-Jie Tong; Zhe Zhang; Xiao-Lin Mu; Zheng-Jia Yi; Shuo Bai; Ke Xu
Journal:  Exp Ther Med       Date:  2012-11-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.